Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | PTGIR | P43119 | 2/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.41 |
| ▸ | GYS1 | P13807 | 2/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913482 | 0.77 | RAB9A (0.46) | CYP3A4ALDH1A1 | |
| SCHEMBL3400744 | 0.75 | SYK (0.41) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL2787581 | 0.75 | CCR6 (0.50) | CCR6PAX8ALDH1A1 | |
| SCHEMBL801192 | 0.73 | CCR6 (0.54) | CCR6PAX8ALDH1A1 | |
| SCHEMBL29144366 | 0.72 | CCR6 (0.46) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| Trifluoroacetic Acid SCHEMBL3400733 | 0.72 | ITGA4 (0.39) | ALDH1A1HDAC3HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL14966519 | 0.72 | BMP1 (0.38) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| Trifluoroacetic Acid SCHEMBL7411923 | 0.71 | CCR6 (0.43) | CCR6PAX8ALDH1A1 | |
| SCHEMBL13500128 | 0.71 | CCR6 (0.45) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| Trifluoroacetic Acid SCHEMBL14966713 | 0.70 | CCR6 (0.39) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | PTGDR2 2156/4885CYP3A4 8/4885CYP2C9 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.